Aligos Therapeutics, Inc.
ALGSNASDAQHealthcare● Active
$5.16
+$0.20(+4.03%)
Market Cap$31931226
P/E Ratio—
52W High$13.689
52W Low$4.8
Aligos Therapeutics, Inc. (ALGS) Earnings: Dates, EPS & Revenue History
Quarterly EPS vs. estimates, revenue surprises, next earnings date, and analyst consensus.
ALGS · earnings · updated Jun 9, 2026
Latest Earnings
Q2 FY2026Report Date: May 7, 2026EPS Actual
-$2.21
Est. -$2.29 · +3.5%
Revenue
$0.00B
Est. $0.00B · +1032.0%
Fiscal Period
Q2 FY2026
FY ends December
Report Date
May 7, 2026
After Market Close
▲ Beat EPS▲ Beat Revenue✓ 2-Quarter EPS Beat Streak
ALGS reports quarterly as a NASDAQ-listed Biotechnology company. Fiscal year ends in December. Data: FMP · Updated hourly.
Next Earnings Date
Days Away
84
days
Expected Date
Sep 1, 2026
Fiscal Period
Q3 FY2026
Release Time
◌ Time TBD (Unconfirmed)EPS Est.
—
Rev. $6.21B
Days Away84
Expected DateSep 1, 2026
Fiscal PeriodQ3 FY2026
Release TimeTime TBD (Unconfirmed)
EPS Est.—
Rev. Est.$6.21B
EPS & Revenue vs. Estimates
Actual (Beat)
Actual (Miss)
Estimated
Earnings History
| Period | Report Date | EPS Est. | EPS Actual | EPS Surpr. | Revenue | Rev. Est. | Rev. Surpr. |
|---|---|---|---|---|---|---|---|
| ◌ Q3 FY2026 | Aug 5, 2026 | -$1.25 | — | — | — | $0.02B | — |
| ▲ Q2 FY2026 | May 7, 2026 | -$2.29 | -$2.21 | +3.5% | $0.00B | $0.00B | +1032.0% |
| ▲ Q1 FY2026 | Mar 5, 2026 | -$2.49 | -$1.91 | +23.2% | $0.00B | $0.00B | -61.6% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -$2.09 | -$3.04 | -45.5% | $0.00B | $0.00B | +177.9% |
| ▲ Q3 FY2025 | Aug 6, 2025 | -$2.35 | -$1.53 | +34.9% | $0.00B | $0.00B | +122.7% |
| ▲ Q2 FY2025 | May 6, 2025 | -$2.80 | -$2.11 | +24.6% | $0.00B | $0.00B | -37.8% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -$2.63 | -$3.41 | -29.7% | $0.00B | $0.00B | +25.8% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -$2.15 | -$3.07 | -42.8% | $0.00B | $0.00B | +192.8% |
Q3 FY2026
Aug 5, 2026
EPS Actual
—
EPS Est.
-$1.25
EPS Surpr.
—
Revenue
—
Q2 FY2026
May 7, 2026Beat
EPS Actual
-$2.21
EPS Est.
-$2.29
EPS Surpr.
+3.5%
Revenue
$0.00B
Q1 FY2026
Mar 5, 2026Beat
EPS Actual
-$1.91
EPS Est.
-$2.49
EPS Surpr.
+23.2%
Revenue
$0.00B
Q4 FY2025
Nov 6, 2025Miss
EPS Actual
-$3.04
EPS Est.
-$2.09
EPS Surpr.
-45.5%
Revenue
$0.00B
Q3 FY2025
Aug 6, 2025Beat
EPS Actual
-$1.53
EPS Est.
-$2.35
EPS Surpr.
+34.9%
Revenue
$0.00B
Q2 FY2025
May 6, 2025Beat
EPS Actual
-$2.11
EPS Est.
-$2.80
EPS Surpr.
+24.6%
Revenue
$0.00B
Q1 FY2025
Mar 10, 2025Miss
EPS Actual
-$3.41
EPS Est.
-$2.63
EPS Surpr.
-29.7%
Revenue
$0.00B
Q4 FY2024
Nov 6, 2024Miss
EPS Actual
-$3.07
EPS Est.
-$2.15
EPS Surpr.
-42.8%
Revenue
$0.00B
Analyst Estimates
Limited analyst coverage (fewer than 3 analysts). Estimates may not reflect market consensus.
EPS Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $-1.07 | $-1.07 | $-1.07 | 1 |
| Q3 FY2027 | $-1.21 | $-1.21 | $-1.21 | 1 |
| Q2 FY2027 | $-1.20 | $-1.20 | $-1.20 | 1 |
| Q1 FY2027 | $-1.53 | $-1.53 | $-1.53 | 1 |
| Q4 FY2026 | $-1.90 | $-1.90 | $-1.90 | 1 |
| Q3 FY2026 | $-2.95 | $-2.21 | $-1.45 | 3 |
Revenue Estimates
| Period | Low | Consensus | High | # Analysts |
|---|---|---|---|---|
| Q4 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q3 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q2 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q1 FY2027 | $0.0B | $0.0B | $0.0B | 3 |
| Q4 FY2026 | $0.0B | $0.0B | $0.0B | 5 |
| Q3 FY2026 | $0.0B | $0.0B | $0.0B | 6 |
Earnings Price Reaction
Closing price one trading day before vs. one trading day after each earnings release.
| Period | Report Date | EPS Beat/Miss | Price Before | Price After | 1D Reaction |
|---|---|---|---|---|---|
| ▲ Q2 FY2026 | May 7, 2026 | +3.5% | $6.37 | $6.03 | -5.34% |
| ▲ Q1 FY2026 | Mar 5, 2026 | +23.2% | $6.86 | $6.66 | -2.92% |
| ▼ Q4 FY2025 | Nov 6, 2025 | -45.5% | $7.33 | $7.10 | -3.14% |
| ▲ Q3 FY2025 | Aug 6, 2025 | +34.9% | $7.91 | $8.04 | +1.64% |
| ▲ Q2 FY2025 | May 6, 2025 | +24.6% | $5.05 | $4.58 | -9.31% |
| ▼ Q1 FY2025 | Mar 10, 2025 | -29.7% | $12.94 | $10.41 | -19.55% |
| ▼ Q4 FY2024 | Nov 6, 2024 | -42.8% | $9.83 | $9.35 | -4.88% |
| ▲ Q3 FY2024 | Aug 6, 2024 | +118.8% | $11.50 | $11.18 | -2.78% |
Q2 FY2026-5.34%
Report Date
May 7, 2026
EPS Beat/Miss
+3.5%
Price Before
$6.37
Price After
$6.03
Q1 FY2026-2.92%
Report Date
Mar 5, 2026
EPS Beat/Miss
+23.2%
Price Before
$6.86
Price After
$6.66
Q4 FY2025-3.14%
Report Date
Nov 6, 2025
EPS Beat/Miss
-45.5%
Price Before
$7.33
Price After
$7.10
Q3 FY2025+1.64%
Report Date
Aug 6, 2025
EPS Beat/Miss
+34.9%
Price Before
$7.91
Price After
$8.04
Q2 FY2025-9.31%
Report Date
May 6, 2025
EPS Beat/Miss
+24.6%
Price Before
$5.05
Price After
$4.58
Q1 FY2025-19.55%
Report Date
Mar 10, 2025
EPS Beat/Miss
-29.7%
Price Before
$12.94
Price After
$10.41
Q4 FY2024-4.88%
Report Date
Nov 6, 2024
EPS Beat/Miss
-42.8%
Price Before
$9.83
Price After
$9.35
Q3 FY2024-2.78%
Report Date
Aug 6, 2024
EPS Beat/Miss
+118.8%
Price Before
$11.50
Price After
$11.18
Avg Beat Reaction-3.74%
Avg Miss Reaction-9.19%
Beat Rate5 / 8 quarters
Largest Move-19.55% (Q1 FY2025)
Data: FMP /historical-price-eod/full · field: close
About Earnings & Data Methodology
Data source: Financial Modeling Prep (FMP) | Updated: Hourly | Surprise%: (Actual − Estimate) / |Estimate| × 100 | Fiscal year: ALGS ends December
Aligos Therapeutics, Inc. (ALGS) most recently reported earnings on May 7, 2026 for Q2 FY2026, posting EPS of $-2.21 — beating the analyst consensus of $-2.29 by +3.5%. ALGS has beaten EPS estimates for 2 consecutive quarters. The next ALGS earnings date is expected around September 1, 2026.
Each quarter, investors track ALGS earnings for signals on forward guidance and business momentum. For longer-term revenue trends, see the Revenue tab. ALGS revenue tab →
Earnings Glossary
EPS (Earnings Per Share)
Net income ÷ diluted shares outstanding. The primary metric analysts use to gauge quarterly profitability.
Earnings Surprise %
(Actual − Estimate) / |Estimate| × 100. Positive = Beat. Negative = Miss.
Beat / Miss / In-Line
Beat = Actual ≥ Estimate. Miss = Actual < Estimate. In-Line = within ±1%.
BMO / AMC
Before Market Open / After Market Close. Two windows when companies typically release results.
Fiscal Quarter
ALGS's fiscal year ends in December. Fiscal quarters may not align with calendar quarters.
Analyst Consensus
Average EPS/Revenue forecast across all covering analysts. More analysts = more reliable estimate.
Figures tie to FMP earnings calendar, estimates, and SEC 10-Q/10-K filings where noted.
Frequently asked questions
ALGS earnings · 5 questionsAligos Therapeutics, Inc.'s next earnings report is expected around September 1, 2026. ALGS typically reports quarterly — approximately every three months. The exact date is confirmed by the company 2–4 weeks before the release. Time is currently TBD; ALGS historically reports after market close (AMC).
ALGS earnings datewhen is ALGS earningsALGS next earnings datewhen does ALGS report earningsALGS earnings calendar
▸ Source: FMP · Aligos Therapeutics, Inc. SEC filings · US GAAP · Aligos Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 9, 2026